Cargando…

APOE allele frequencies in suspected non-amyloid pathophysiology (SNAP) and the prodromal stages of Alzheimer’s Disease

Biomarker definitions for preclinical Alzheimer’s disease (AD) have identified individuals with neurodegeneration (ND+) without β-amyloidosis (Aβ-) and labeled them with suspected non-AD pathophysiology (SNAP). We evaluated Apolipoprotein E (APOE) ε2 and ε4 allele frequencies across biomarker defini...

Descripción completa

Detalles Bibliográficos
Autores principales: Hohman, Timothy J., Dumitrescu, Logan, Oksol, Amy, Wagener, Madison, Gifford, Katherine A., Jefferson, Angela L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5708777/
https://www.ncbi.nlm.nih.gov/pubmed/29190651
http://dx.doi.org/10.1371/journal.pone.0188501
_version_ 1783282681577996288
author Hohman, Timothy J.
Dumitrescu, Logan
Oksol, Amy
Wagener, Madison
Gifford, Katherine A.
Jefferson, Angela L.
author_facet Hohman, Timothy J.
Dumitrescu, Logan
Oksol, Amy
Wagener, Madison
Gifford, Katherine A.
Jefferson, Angela L.
author_sort Hohman, Timothy J.
collection PubMed
description Biomarker definitions for preclinical Alzheimer’s disease (AD) have identified individuals with neurodegeneration (ND+) without β-amyloidosis (Aβ-) and labeled them with suspected non-AD pathophysiology (SNAP). We evaluated Apolipoprotein E (APOE) ε2 and ε4 allele frequencies across biomarker definitions—Aβ-/ND- (n = 268), Aβ+/ND- (n = 236), Aβ-/ND+ or SNAP (n = 78), Aβ+/ND+ (n = 204)—hypothesizing that SNAP would have an APOE profile comparable to Aβ-/ND-. Using AD Neuroimaging Initiative data (n = 786, 72±7 years, 48% female), amyloid status (Aβ+ or Aβ-) was defined by cerebrospinal fluid (CSF) Aβ-42 levels, and neurodegeneration status (ND+ or ND-) was defined by hippocampal volume from MRI. Binary logistic regression related biomarker status to APOE ε2 and ε4 allele carrier status, adjusting for age, sex, education, and cognitive diagnosis. Compared to the biomarker negative (Aβ-/ND-) participants, higher proportions of ε4 and lower proportions of ε2 carriers were observed among Aβ+/ND- (ε4: OR = 6.23, p<0.001; ε2: OR = 0.53, p = 0.03) and Aβ+/ND+ participants (ε4: OR = 12.07, p<0.001; ε2: OR = 0.29, p = 0.004). SNAP participants were statistically comparable to biomarker negative participants (p-values>0.30). In supplemental analyses, comparable results were observed when coding SNAP using amyloid imaging and when using CSF tau levels. In contrast to APOE, a polygenic risk score for AD that excluded APOE did not show an association with amyloidosis or neurodegeneration (p-values>0.15), but did show an association with SNAP defined using CSF tau (β = 0.004, p = 0.02). Thus, in a population with low levels of cerebrovascular disease and a lower prevalence of SNAP than the general population, APOE and known genetic drivers of AD do not appear to contribute to the neurodegeneration observed in SNAP. Additional work in population based samples is needed to better elucidate the genetic contributors to various etiological drivers of SNAP.
format Online
Article
Text
id pubmed-5708777
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-57087772017-12-15 APOE allele frequencies in suspected non-amyloid pathophysiology (SNAP) and the prodromal stages of Alzheimer’s Disease Hohman, Timothy J. Dumitrescu, Logan Oksol, Amy Wagener, Madison Gifford, Katherine A. Jefferson, Angela L. PLoS One Research Article Biomarker definitions for preclinical Alzheimer’s disease (AD) have identified individuals with neurodegeneration (ND+) without β-amyloidosis (Aβ-) and labeled them with suspected non-AD pathophysiology (SNAP). We evaluated Apolipoprotein E (APOE) ε2 and ε4 allele frequencies across biomarker definitions—Aβ-/ND- (n = 268), Aβ+/ND- (n = 236), Aβ-/ND+ or SNAP (n = 78), Aβ+/ND+ (n = 204)—hypothesizing that SNAP would have an APOE profile comparable to Aβ-/ND-. Using AD Neuroimaging Initiative data (n = 786, 72±7 years, 48% female), amyloid status (Aβ+ or Aβ-) was defined by cerebrospinal fluid (CSF) Aβ-42 levels, and neurodegeneration status (ND+ or ND-) was defined by hippocampal volume from MRI. Binary logistic regression related biomarker status to APOE ε2 and ε4 allele carrier status, adjusting for age, sex, education, and cognitive diagnosis. Compared to the biomarker negative (Aβ-/ND-) participants, higher proportions of ε4 and lower proportions of ε2 carriers were observed among Aβ+/ND- (ε4: OR = 6.23, p<0.001; ε2: OR = 0.53, p = 0.03) and Aβ+/ND+ participants (ε4: OR = 12.07, p<0.001; ε2: OR = 0.29, p = 0.004). SNAP participants were statistically comparable to biomarker negative participants (p-values>0.30). In supplemental analyses, comparable results were observed when coding SNAP using amyloid imaging and when using CSF tau levels. In contrast to APOE, a polygenic risk score for AD that excluded APOE did not show an association with amyloidosis or neurodegeneration (p-values>0.15), but did show an association with SNAP defined using CSF tau (β = 0.004, p = 0.02). Thus, in a population with low levels of cerebrovascular disease and a lower prevalence of SNAP than the general population, APOE and known genetic drivers of AD do not appear to contribute to the neurodegeneration observed in SNAP. Additional work in population based samples is needed to better elucidate the genetic contributors to various etiological drivers of SNAP. Public Library of Science 2017-11-30 /pmc/articles/PMC5708777/ /pubmed/29190651 http://dx.doi.org/10.1371/journal.pone.0188501 Text en © 2017 Hohman et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Hohman, Timothy J.
Dumitrescu, Logan
Oksol, Amy
Wagener, Madison
Gifford, Katherine A.
Jefferson, Angela L.
APOE allele frequencies in suspected non-amyloid pathophysiology (SNAP) and the prodromal stages of Alzheimer’s Disease
title APOE allele frequencies in suspected non-amyloid pathophysiology (SNAP) and the prodromal stages of Alzheimer’s Disease
title_full APOE allele frequencies in suspected non-amyloid pathophysiology (SNAP) and the prodromal stages of Alzheimer’s Disease
title_fullStr APOE allele frequencies in suspected non-amyloid pathophysiology (SNAP) and the prodromal stages of Alzheimer’s Disease
title_full_unstemmed APOE allele frequencies in suspected non-amyloid pathophysiology (SNAP) and the prodromal stages of Alzheimer’s Disease
title_short APOE allele frequencies in suspected non-amyloid pathophysiology (SNAP) and the prodromal stages of Alzheimer’s Disease
title_sort apoe allele frequencies in suspected non-amyloid pathophysiology (snap) and the prodromal stages of alzheimer’s disease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5708777/
https://www.ncbi.nlm.nih.gov/pubmed/29190651
http://dx.doi.org/10.1371/journal.pone.0188501
work_keys_str_mv AT hohmantimothyj apoeallelefrequenciesinsuspectednonamyloidpathophysiologysnapandtheprodromalstagesofalzheimersdisease
AT dumitresculogan apoeallelefrequenciesinsuspectednonamyloidpathophysiologysnapandtheprodromalstagesofalzheimersdisease
AT oksolamy apoeallelefrequenciesinsuspectednonamyloidpathophysiologysnapandtheprodromalstagesofalzheimersdisease
AT wagenermadison apoeallelefrequenciesinsuspectednonamyloidpathophysiologysnapandtheprodromalstagesofalzheimersdisease
AT giffordkatherinea apoeallelefrequenciesinsuspectednonamyloidpathophysiologysnapandtheprodromalstagesofalzheimersdisease
AT jeffersonangelal apoeallelefrequenciesinsuspectednonamyloidpathophysiologysnapandtheprodromalstagesofalzheimersdisease
AT apoeallelefrequenciesinsuspectednonamyloidpathophysiologysnapandtheprodromalstagesofalzheimersdisease